/
NKTX
$2.85+$0.02 (+0.71%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$202.5M
72M shares
52-week range
$1.63 – $3.65
60% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.43%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-27.82
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.5M | $115.4K | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $4.3M | $17.2K | $0 | $0 | $0 | $5.9M | $0 | $9.2M |
| Gross profit | $2.3M | $98.2K | $0 | $0 | $0 | −$5.9M | $0 | −$9.2M |
| Gross margin | 35.1% | 85.1% | — | — | — | — | — | — |
| R&D | $4.3M | $17.2M | $36.2M | $63.4M | $90.9M | $90.9M | $96.7M | $90.4M |
| Operating income | −$356.4K | −$22.3M | −$51.5M | −$86.4M | −$119.0M | −$131.7M | −$128.2M | −$121.2M |
| EBITDA | −$91.3K | −$20.0M | −$50.7M | −$84.3M | −$105.6M | −$120.5M | −$99.6M | −$94.9M |
| Net income | −$274.5K | −$21.1M | −$91.4M | −$86.1M | −$113.8M | −$117.5M | −$108.8M | −$104.1M |
| Net margin | -4.2% | -18265.7% | — | — | — | — | — | — |
| EPS (diluted) | -0.01 | -2.55 | -1.59 | -2.62 | -2.61 | -2.40 | -1.60 | -1.41 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-1.44 | $-1.64–$-1.09 | 3 |
| 2027 | $7M | $-1.39 | $-2.11–$-0.56 | 3 |
| 2028 | $4M | $-1.22 | $-1.29–$-1.12 | 3 |
| 2029 | $86M | $-0.80 | $-0.80–$-0.80 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Nkarta, Inc. Common Stock
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
www.nkartatx.com- Employees
- 108
- IPO / List date
- Jul 10, 2020
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds NKTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,732,372 | $3.7M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NKTX yet.
